Apotex FDA Wednesday, December 21, 2022 0.00 Neutral

FDA Approves BRIMONIDINE TARTRATE — Apotex Corp.

# FDA Approves Generic Brimonidine Tartrate from Apotex Corp. The FDA has approved Apotex Corp.'s abbreviated new drug application for generic brimonidine tartrate ophthalmic solution, expanding treatment options for glaucoma and ocular hypertension patients and intensifying competitive pressure in the ophthalmic alpha-agonist market. The approval is expected to increase price competition and improve patient accessibility to this widely-prescribed eye medication.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day